A novel HPLC system has been developed that has allowed the separation of tamoxifen DNA adducts formed in the livers of rats and mice treated with this drug. At least 13 different peaks have been separated from 32 P-post-labelled DNA, with two major peaks jointly accounting for Ͼ60% of the total adducts formed by tamoxifen in the livers of treated rats and mice. This is a great improvement on the resolution obtained by thin layer chromatography, which separates the adducts into one main product consisting of a group of major adduct spots eluting together, plus several other minor spots. Identification of the nature of some of the peaks has been investigated. Comparisons of the products formed when α-acetoxytamoxifen is reacted with DNA in vitro with 32 P-post-labelled liver DNA adducts from rats treated with tamoxifen or α-hydroxytamoxifen in vivo, appear to confirm that a major route of activation of tamoxifen in vivo is via α-hydroxylation. The resolving power of this HPLC system has further extended this result to show that six of the peaks, including the two major peaks, are formed by the reaction of an activated α-hydroxytamoxifen with DNA. Activation of 4-hydroxytamoxifen by the peroxidase/H 2 O 2 system in vitro gives a more polar DNA adduct seen only at trace levels in liver DNA from tamoxifen-treated rats and mice.
Introduction
The anti-oestrogen, tamoxifen (Z-1-[4-(dimethylaminoethoxy)-phenyl]1,2-diphenyl-1-butene), is an hepatocarcinogen in rats following short-term (1) and long-term (2-5) dosing. Using the 32 P-post-labelling assay, large numbers of DNA adducts were detected in rat liver following tamoxifen treatment (5, 6) . Adducts increase in rat liver in a time-dependent manner with continued dietary exposure (~40 mg tamoxifen/kg per day) and plateau between 3 and 6 months with levels of~3000 adducts/10 8 nucleotides (5) . Mice are resistant to the carcinogenic effects of tamoxifen (7) . DNA adducts are detected in mouse liver following oral (8) (9) (10) and i.p. (11) dosing, but are present at lower levels than similarly treated rats (10) . With long-term dietary exposure (~40 mg tamoxifen/kg per day) adducts are present in mouse liver at 3 months (~67 adducts/ 10 8 nucleotides), but decrease with time and are not detectable in tamoxifen-treated mice by 2 years (10) .
In the 32 P-post-labelling assay, radiolabelled nucleotides are separated by either thin layer chromatography (TLC*) or high performance liquid chromatography (HPLC). TLC separation of DNA from the livers of tamoxifen-treated rats gives a large radioactive area composed of several poorly resolved products that elute together, plus a few minor spots (see Figure 2a and ref. 5) . When DNA from the livers of tamoxifen-treated mice is separated by TLC under the same conditions, only the major adduct spot is observed, which is composed of at least two products (10) .
32 P-Post-labelled DNA from the livers of tamoxifen-treated rats has been separated by HPLC to yield between one and five individual peaks depending on the mobile phase used (12) (13) (14) . Osbourne and co-workers (12) used the monophosphate version of the post-labelling assay in which 32 P-labelled 5Ј-monophosphates are separated. HPLC separation was achieved using a sodium phosphate buffer with an increasing methanol gradient over 100 min. When liver from a tamoxifen-treated rat was analysed using this system, three peaks were detected, which co-eluted with three peaks obtained with DNA samples reacted in vitro with α-hydroxytamoxifen and α-acetoxytamoxifen. A more recent publication by Koskinen and co-workers (14) used the bisphosphate version of the post-labelling assay in which 32 P-labelled 3Ј5Ј-bisphosphates are separated. HPLC analysis of post-labelled DNA from the livers of tamoxifentreated rats gave five individual peaks by using their ammonium formate-phosphoric acid-methanol gradient. Tamoxifen adducts are eluted after 60 min.
Since tamoxifen forms a large number of different DNA adducts, which to date have been inadequately separated from one another, we attempted to improve this separation and thereby develop a method that would ultimately help in adduct identification. In this article we describe a novel HPLC system that is capable of separating the 32 P-labelled DNA adducts of tamoxifen-treated rats into at least 12 peaks. Our method uses higher salt concentrations (2 M) than described in the studies above. This was adapted from Möller and Zeisig (15) who originally developed this method for the separation of 2-nitrofluorene and N-acetyl-2 aminofluorene DNA postlabelled adducts. We have used our system to compare liver DNA samples from tamoxifen-treated mice and rats, and also DNA treated with a model of the reactive metabolite of tamoxifen, α-acetoxytamoxifen. Using a horseradish peroxidase/H 2 O 2 model activating system, the difference in the DNA adducts formed from 4-hydroxytamoxifen and α-acetoxytamoxifen are clearly demonstrated.
Materials and methods

Chemicals
Tamoxifen was a gift from Dr J.Topham, Zeneca plc, Macclesfield, UK. 4-Hydroxytamoxifen (~1:1 mixture of the E and Z isomers) was a gift from Laboratoires Besin Iscovesco (Paris, France). Both these were Ͼ98% purity as assessed by capillary GLC or UV absorption following HPLC. Tricapylin, micrococcal nuclease, potato apyrase (grade VI), dithiothreitol, spermidine, ribonuclease A and T 1 , HEPES, hydrogen peroxide, horseradish peroxidase and calf-thymus DNA were from Sigma Chemical Co. (Poole, Dorset, UK). T4 Polynucleotide kinase (3Ј-phosphatase-free) and calf spleen phosphodiesterase were from Boehringer Mannheim (Lewes, East Sussex, UK). Water saturated phenol was from Rathburn Chemicals (Peebleshire, Scotland). [γ-32 P]ATP (Ͼ185 TBq/mmol, 370 MBq/ml) was from Amersham International (Amersham, Buckinghamshire, UK). PEI-cellulose thin layer plates were from Macherey Nagel (supplied by Camlab, Cambridge, UK). The remaining chemicals of the highest available quality, except where indicated, were from Merck Ltd (Lutterworth, Leicestershire, UK) or Fisher Scientific UK (Loughborough, Leicestershire, UK).
Synthesis of trans α-hydroxytamoxifen and trans α-acetoxytamoxifen
The trans isomer of α-hydroxytamoxifen was synthesized using the method described by Foster and co-workers (16) . trans α-acetoxytamoxifen was prepared from trans α-hydroxytamoxifen using the published method (17) .
Animal treatments
Tamoxifen. Dosing regimes were used to maximize the extent of hepatic DNA damage in rats (5) and mice (10) . Female Wistar rats (LAC-P), from Harlan Olac Ltd, 6 weeks old, were fed either powdered control diet or one containing 420 p.p.m. tamoxifen (0.42 g tamoxifen/kg diet) (5). The tamoxifen diet was made up monthly and protected from light. Animals were killed after 6 months, the livers were removed, immediately frozen in liquid nitrogen and stored at -80°C. For mice, female DBA/2 (20-25 g) from Harlan Olac Ltd, were administered tamoxifen by gavage daily for 30 days at 120 mg/kg dissolved in tricapylin (0.05-0.1 ml). Controls received vehicle only. Animals were killed 24 h after the last dose, the livers were removed, immediately frozen in liquid nitrogen and stored at -80°C. α-Hydroxytamoxifen. Female F344 rats (6 weeks old), from Harlan Olac Ltd, received 0.11 mmol/kg of trans α-hydroxytamoxifen (equivalent to 40 mg/kg tamoxifen) by i.p. for 4 days. Dosing suspensions were made up in tricaprylin (0.11 mmol/ml). The animals were killed 24 h after the last dose. The livers were removed, immediately frozen in liquid nitrogen and stored at -80°C.
In vitro reaction of enzymatically activated 4-hydroxytamoxifen and tamoxifen
with DNA Calf-thymus DNA (100 µg) in 10 µl 1:100 SSC-EDTA (0.15 M NaCl and 0.015 M sodium citrate-0.1 mM EDTA) was added to a mixture containing 0.05 M HEPES/NaOH buffer, pH 7.2, Tween 20 (0.03%, v/v), 200 µM EDTA, 250 µM H 2 O 2 and horseradish peroxidase (HRP) (1000 AU/min,~20 µg protein) to give a final volume of 400 µl. After equilibration to 37°C, reactions were started by the addition of 4-hydroxytamoxifen or tamoxifen (160 µM, dissolved in 2.5 µl DMSO) and incubated at 37°C for 30 min in the case of 4-hydroxytamoxifen or 4 h for tamoxifen. The reaction was stopped by the addition of CHCl 3 (1 ml) at -20°C. Unbound compound was removed by ether extraction (4ϫ700 µl) and DNA precipitated from the aqueous phase by addition of 50 µl 5 M NaCl and 1 ml ice-cold ethanol.
In vitro reaction of α-acetoxytamoxifen with DNA Calf thymus DNA (500 µg) in 500 µl 1:100 SSC-EDTA buffer was added to 55 µg α-acetoxytamoxifen dissolved in 150 µl of ethanol and incubated at 37°C overnight. Unreacted compound was removed by ether extraction (4ϫ700 µl) and DNA precipitated from the aqueous phase by addition of 50 µl 5 M NaCl and 1 ml ice-cold ethanol.
After centrifugation and removal of the supernatant, the DNA from both reactions was washed with 1 ml 70% then 100% ethanol before being redissolved in 500 µl 1:100 SSC-EDTA buffer.
DNA isolation and 32 P-post-labelling DNA was isolated from livers by the method of Gupta (18) . DNA samples were subjected to 32 P-post-labelling as described previously (1) . 32 P-Labelled adducts were subjected to separation by either TLC or HPLC as described below.
TLC conditions 32 P-Post-labelled samples were applied to 10ϫ15 cm plastic backed PEIcellulose TLC plates. TLC plates were developed firstly in D1 (1.7 M sodium phosphate pH 7.0) on to filter paper wicks. Adducts were then separated by two-dimensional chromatography using solvent systems D2 (2.6 M lithium formate, 6.4 M urea. pH 3.5) and D3 (0.6 M lithium chloride, 6.4 M urea, 0.4 M Tris-HCl, pH 8.0). Finally, plates were developed in D4 (same as D1) on to a filter paper wick (5, 8) . Adducts were visualized by autoradiography using OMAT-AR film with intensifying screens for between 5 min and 24 h at room temperature or -80°C. Adduct spots were excised from the plates and radioactivity quantified by scintillation counting. Mean levels of adducts Ϯ SD are expressed as relative adduct labelling (RAL) (19) .
In some instances HPLC fractions were collected, dried down in a speed vac (Savant) and applied to TLC plates. Plates were washed twice for 5 min in water to remove ammonium formate and dried. Adducts were separated as above, omitting the initial D1 step, and visualized using autoradiography.
HPLC instrumentation
The HPLC system consisted of an autosampler with a 200-µl loop (Varian Star 9300) linked to an automated solid phase extraction (SPE) sample preparation system (Varian Prospekt) consisting of a 9200 Prospekt controller and a Prospekt solvent delivery unit. Samples were loaded onto Prospekt cartridges (Bondesil C18, octadecyl) and the adducted 32 P-labelled nucleotides were eluted onto an HPLC column (Hypersil BDS C18, 250ϫ4.6 mm, 5 µ, Shandon). The HPLC pump was a Varian Star 9012. Eluate passed through a UV-Vis detector (Varian Star 9050) and a radiochemical detector (LabLogic, β-ram) with a solid phase cell (500 µl). Data analysis was by Laura, an MS Windows package (LabLogic).
HPLC sample preparation
Since the samples contained relatively high levels of 32 P label, appropriate precautions were taken to minimize human exposure. This was achieved by using an automated SPE sample preparation system. The SPE cartridge was activated by methanol (2 ml/min for 3 min) and then washed with 0.5 M ammonium formate pH 4.0 (2 ml/min for 3 min). 32 P-Labelled DNA samples (in 200 µl) were loaded onto the SPE cartridge via the autosampler, and normal nucleotides, excess [γ-32 P]ATP and any other non-adduct material was washed from the cartridge in 0.5 M ammonium formate, pH 4.0 (0.4 ml/min for 5 min). At this time the cartridge was switched into the HPLC system solvent flow and the analysis started.
HPLC conditions
HPLC analysis was performed at ambient temperature. For optimization of the HPLC chromatography conditions, solvent A was 2 M ammonium formate pH 4.0. This was prepared by dissolving ammonium formate salt in water to 2 M and adjusting the pH to 4.0 with formic acid. Solvent B was either acetonitrile or methanol, or a mix of the two solvents. Different isocratic and linear gradients were investigated. Optimum separation was achieved with 1 ml/min of 80% (i) 2 M ammonium formate pH 4.0, 20%, (ii) acetonitrile:methanol (6:1, v/v) for 40 min followed by a linear gradient of 20-45% (ii) for 20 min. The HPLC conditions were sufficient to remove all radioactivity from the system, but as a precaution the system was washed for 20 min in 50% (i) and (ii) between runs.
HPLC adduct calculations
Known amounts of ATP were injected onto the HPLC, a peak (eluting at 3 min) was collected and radioactivity measured in disintegrations per min 
Results
Optimization of 32 P-HPLC conditions for resolving the tamoxifen 32 P-post-labelled nucleotides HPLC gradient. Different HPLC gradients were investigated for separating the 32 P-post-labelled tamoxifen DNA adducts in rat liver. Initially solvent B was acetonitrile, good separation of adducts was achieved but the main peaks did not elute until 30-48 min. Attempts were made to achieve optimum resolution. By reducing the percentage of ammonium formate in the isocratic part of the analysis and introducing a small percentage of methanol to the acetonitrile, optimal conditions were achieved (Figure 1) . Sample preparation. To investigate whether the automated SPE sample preparation system (utilizing Bondesil C18 cartridges) led to a loss of 32 P-labelled adducts, 1 µg of rat liver DNA from a rat treated with tamoxifen for 6 months was post-labelled and subjected to HPLC separation with and without SPE (Figure 1 ). Approximately 86% of the radioactivity was removed when SPE was used. The initial [γ-32 P]ATP peak was significantly reduced when SPE was used, and decreased from~88% of the total radioactivity in the analysis to~11% with SPE. The area of the individual adduct peaks was similar both with and without SPE, although~14% of the total radioactivity in the adduct peaks was lost with SPE (Table I) . Reproducibility of HPLC procedure. Using liver DNA from a rat treated with tamoxifen for 6 months, the inter-experimental coefficient of variation of the HPLC method using direct injection was 14.5%. This is an improvement on the reproducibility of the corresponding TLC procedure (5). Using HPLC, this sample gave total levels of 3983 Ϯ 578 adducts/10 8 nucleotides (mean Ϯ SD, n ϭ 5) compared with TLC, which gave levels of 2431 Ϯ 1535 adducts/10 8 nucleotides (mean Ϯ SD, n ϭ 6).
Comparison of TLC and HPLC separation of 32 P-post-labelled rat and mouse DNA adducts in liver from tamoxifen-treated animals 32 P-Post-labelled rat and mouse liver DNA adducts were separated by either TLC (Figure 2 ) or by HPLC (Figure 3) . TLC. TLC separation of 32 P-post-labelled DNA from the livers of rats that had been exposed to tamoxifen gives a group of major adduct spots located in the top right hand quarter of the plate, with other minor spots located towards the origin ( Figure  2A ). TLC separation of post-labelled DNA from the livers of treated mice results in a group of major adducts located towards the top right hand corner of the TLC plate ( Figure  2B ). This appears to co-elute with the major adducts detected in rat liver. No adducts were observed in the control rat and mouse samples (data not shown). HPLC. Initially, HPLC was performed without SPE to insure that the maximum amount of adducts could be collected for identification by TLC. HPLC separation of post-labelled DNA adducts from the livers of tamoxifen-treated rats (2 µg) produces at least 12 individual radioactive peaks that elute between 15 and 56 min ( Figure 3A ), compared with controls where no peaks were observed ( Figure 3B ). There were two main peaks (5 and 6) that eluted at~28 and 32 min, respectively. These account for~45 and 24% of adducts respectively (Table II) . HPLC separation of post-labelled DNA adducts from the livers of tamoxifen-treated mice (10 µg) produces up to 13 individual radioactive peaks eluting between 15 and 55 min ( Figure 3C ). No radioactive peaks were observed for elution over this time period in the controls ( Figure 3D) ; however, the two peaks that eluted at 60 min in the treated sample ( Figure 3C ) were also present in the control ( Figure 3D ). By analysing a mixture of post-labelled rat and mouse DNA together, it was confirmed that the majority of peaks from treated mouse liver co-eluted with those observed in the rat liver and they were numbered accordingly. There were two main peaks (5 and 6). which elute at~28 and 33 min, respectively. These account for~38 and 25% of adducts, respectively (Table II) . In the mouse, the third largest peak was number 7, which eluted at 47 min (~8% of adducts): it was also observed in the rat but at a much lower level (~0.2% of adducts). There was a small extra peak observed in the mouse which was absent from the rat (peak 13).
To identify which HPLC peaks from the treated rat and mouse DNA represent which TLC spots, HPLC peaks were collected, dried down and separated by TLC. Peaks 5 and 6 in both the rat and mouse account for the majority of the main spot observed with TLC. Peak 7 and peak 13 which was only observed in the mouse, eluted to the region of the main spot with TLC. Peaks 1-4 also eluted to the region of the main spot, but had components that eluted even further into the top right hand corner of the TLC plate. Peak 11, and also a component of peak 3, co-eluted to a region away from the main spot towards the origin. It is unclear exactly where peaks 8, 9, 10 and 12 elute to with TLC, but they appear to move to the region of the main adduct spot. TLC and HPLC separation of 32 P-post-labelled rat liver DNA from animals treated with trans α-hydroxytamoxifen for 4 days 32 P-Post-labelled liver DNA from a rat treated with trans α-hydroxytamoxifen gave a TLC pattern of adducts and an HPLC trace with a similar number of peaks as those seen in the tamoxifen treated rat sample ( Figure 2C and 4A). The major peak in the trans α-hydroxytamoxifen samples co-eluted with peak number 6 in the tamoxifen-treated rat, and the second major peak in the trans α-hydroxytamoxifen samples co-eluted with peak number 5 in the rat. These two peaks accounted for 63 and 23% of adducts, respectively (Table II) . TLC and HPLC separation of 32 P-post-labelled DNA treated in vitro with α-acetoxytamoxifen or peroxidase activated 4-hydroxytamoxifen and tamoxifen TLC analysis of DNA reacted directly with α-acetoxytamoxifen gave a pattern of adducts similar to that observed in the tamoxifen-treated rat samples ( Figure 2D ). HPLC analysis of α-acetoxytamoxifen-treated DNA gave a chromatogram with six peaks that co-eluted with peak numbers 3-6, 11 and 12 in post-labelled rat liver DNA ( Figure 4B ). Cochromatography was confirmed by injecting a mix of DNA treated with α-acetoxytamoxifen and DNA from the liver of a tamoxifen-treated rat. The major peak in the α-acetoxytamoxifen-treated DNA was number 6 and accounted for~81% of total adducts (Table II) .
TLC analysis of 4-hydroxytamoxifen-treated DNA gave one major spot ( Figure 2E ). HPLC analysis gave a chromatogram with one major peak ( Figure 4C, peak b) , which co-eluted with peak number 1 in post-labelled DNA from the liver of a tamoxifen-treated rat ( Figure 4A ), and this was confirmed by injecting a mix of the two samples. This major peak accounted for~85% of the adducts. Two other peaks (a and c) were also detected in the 4-hydroxytamoxifen-treated DNA, and eluted at~15 and 27 min. These two peaks did not co-elute with any peaks detected in DNA from the liver of a tamoxifen-treated rat. The first of these eluted just before peak 1 and the second eluted between peaks 4 and 5. The peaks accounted for~6 and 9% of total adducts, respectively. TLC analysis of DNA treated with horseradish peroxidase- The amount of DNA in each analysis is shown in parentheses. HPLC analysis was performed without solid phase extraction to ensure maximal amounts of adducts were collected for TLC identification. Peaks co-eluting with the rat peaks were allocated the same number. Number 13 was allocated to the mouse peak eluting at 40 min, which was absent in the rat.
activated tamoxifen gives a pattern of adducts similar to that observed in the rat ( Figure 2F ). HPLC analysis gave a single major peak that co-eluted with peak 6 ( Figure 4D ).
Discussion
Tamoxifen forms a large number of different DNA adducts in vivo. The relationship between the concentrations of these adducts and their biological significance with respect to hepatocarcinoma is as yet to be established. The majority of tamoxifen 1065 adducts are not adequately separated using 32 P-post-labelling followed by TLC. Because of this, and the lack of absolute standards for tamoxifen adducts (which can be post-labelled), the detection and characterization of adducts formed in rat and mouse liver is complex. To help with this problem, we have developed a novel HPLC system that has improved the separation of tamoxifen DNA adducts. The chemical structure of the adducts within each peak have not been fully characterized, with the exception of peak number 6, which corresponds to the major deoxyguanosine adduct described by Phillips and co-workers (21) . We have also established the nature of the tamoxifen active metabolite responsible for the generation of the adducts within each of the other major peaks.
HPLC conditions
The HPLC method we have described for the separation of 32 P-post-labelled tamoxifen DNA adducts offers better separation than is achieved by the conventional TLC method. The use of SPE, prior to the cartridge being switched into the HPLC solvent flow, removes Ͼ85% of excess radioactivity and thereby significantly reduces operator exposure. This step serves a similar purpose as the attachment of filter paper wicks in the D1 and D4 dimensions when TLC is used. The SPE and filter paper wicks remove excess [γ-32 P]ATP, inorganic phosphate, normal nucleotides and other non-adduct material from the post-labelled reaction mix prior to the separation of adducts. When SPE was used, the total amount of radioactivity in the adduct peaks was reduced uniformly by~14%, which allowed SPE to be utilized except when adduct levels were very low.
Adduct detection limits
When 32 P-post-labelled tamoxifen DNA adducts are separated by conventional TLC, the limit of detection in our laboratory is~0.5 adducts/10 10 nucleotides. In the HPLC system we describe here, the limit of detection was calculated as~1 adduct/10 9 nucleotides. The detection limits were calculated assuming the labelling efficiency is 100%. Since no adduct standards are available in the 3Ј monophosphate form which can be post-labelled, and some of the adducts remain unidentified, the adduct levels reported here are minimum values.
Comparison of HPLC and TLC tamoxifen adducts in rats and mice
We attempted to find a UV marker that would elute with the adducts in the isocratic part of the analysis. This would have allowed separate HPLC chromatograms to be aligned with each other and to identify co-eluting peaks. Different compounds were tested that could be retained on the column for the appropriate time and that could exhibit a high UV absorbance; these included various modified bases and protected amino acids. None were found to be suitable as they eluted too late in the region of increasing acetonitrile/methanol. Because of this, co-chromatography of peaks between different samples could only be demonstrated by performing an HPLC analysis on a mix of the two samples in question. HPLC analysis of post-labelled tamoxifen-treated rat and mouse liver DNA allowed 12 co-eluting peaks to be resolved plus an extra small peak in the mouse. The majority of these peaks (1-6, 8, 9, 10 and 12) elute in the same region on TLC as the major 32 P-labelled product, which demonstrates that this spot is formed from a number of different adducts that elute together. The two major HPLC peaks, 5 and 6, jointly account for 70 and 63% of the adducts formed in vivo in rat and mouse liver, respectively.
Tamoxifen requires metabolic activation to become a DNA binding intermediate. At least two distinct metabolic pathways lead to DNA adduct formation, the first is via α-hydroxytamoxifen (21-23) and the second is via an arene oxide or 4-hydroxylation, which leads to the formation of a quinone methide (24) (25) (26) . Adduct peaks formed by 4-hydroxytamoxifen HPLC analysis of post-labelled DNA reacted in vitro with 4-hydroxytamoxifen gave one major peak that co-eluted with rat peak number 1. This clearly demonstrates that 4-hydroxytamoxifen does not lie on the pathway leading to the formation of the major rat liver DNA adducts in vivo. When tamoxifen was used as a substrate in this model peroxidase/H 2 O 2 activation system, the major post-labelled DNA adduct peak corresponded in retention time to rat peak 6, with the formation of little or none of peak 1. This confirmed the earlier finding that no ring-hydroxylated metabolites are produced in this system (27) . Our results suggest that the active metabolites of the tamoxifen/peroxidase/H 2 O 2 system gives the same DNA adducts as that of α-hydroxytamoxifen. However, it should be noted that the results obtained with the in vitro peroxidase activation system are not quantitative. This is because protein is present in the reaction, and since tamoxifen metabolites have a higher binding affinity with protein than DNA (28), they could be reacting preferentially with this macromolecule. Adduct peaks formed by α-hydroxy and α-acetoxytamoxifen Since rats had not been treated with α-hydroxytamoxifen before, the effect of this compound could not be anticipated. Peaks co-eluting with the rat peaks were allocated the same number. In trace (C), peak a eluted just before peak 1; peak b co-eluted with peak 1 and peak c eluted between peaks 4 and 5.
For this reason, we chose a similar dose level as that used for tamoxifen (40 mg/kg). 32 P-Post-labelled liver DNA from α-hydroxytamoxifen-treated rats gave a similar pattern on TLC as that observed with tamoxifen, but α-hydroxytamoxifen forms~15-fold higher levels than tamoxifen following the same treatment time and dose (unpublished data). The pattern and retention times of 32 P-post-labelled liver DNA adducts following the administration of α-hydroxytamoxifen was the same as that seen after tamoxifen itself. However, HPLC peak 1067 number 6 was the most prominent (as opposed to number 5 with tamoxifen). α-Hydroxytamoxifen would be expected to undergo activation in vivo to an ester, which would react with DNA. Further metabolism may occur via additional routes such as ring hydroxylation, or epoxidation and N-demethylation of the dimethylaminoethoxy side chain. Therefore, administration of trans α-hydroxytamoxifen could produce the full spectrum of DNA adducts formed by tamoxifen, except those that do not involve α-hydroxylation. When α-acetoxytamoxifen is reacted in vitro with DNA, only adducts directly attributed to α-hydroxylation of tamoxifen would be expected to be formed. Separation of these adducts revealed six peaks, the major of which was peak 6. The minor adducts corresponding to peaks 1,2,7-10 were absent. We therefore suggest that the majority of the adducts formed in rat liver by tamoxifen are produced via the α-hydroxylation pathway. Peak b, derived from 4-hydroxytamoxifen, probably contains adducts formed via a quinone methide (25) . Two adducts formed by the reaction of 4-hydroxytamoxifen quinone methide with the N 2 position of deoxyguanosine have been characterized (26) .
Osborne et al. (23) reacted DNA in vitro with α-acetoxytamoxifen and separated three guanosine adducts and one adenosine adduct by HPLC. In their system, the first major eluting peak is a trans form of a deoxyguanosine adduct in which the α position of tamoxifen is linked covalently to the exocyclic amino group of deoxyguanosine-(E)-4-{4-[2-(dimethylamino)ethoxy]phenyl}-3,4-diphenyl-2-(9β-deoxyribofuranosyl-6-oxopurin-2-ylamino)-3-butene (TG1) (21) (22) (23) . The second and third adduct peaks elute together and are the cis isomer of TG1, (Z)-α-(N 2 -deoxyguanosinyl)tamoxifen (TG2) and its diastereoisomer (TG3) respectively. The fourth adduct peak has been identified as a tamoxifen-deoxyadenosine adduct (23) . In the present study, post-labelled DNA reacted with α-acetoxytamoxifen gives one major HPLC peak (number 6), therefore, we propose that when adducts are present as bisphosphates, the geometric or stereoisomers of the deoxyguanosine adducts are not resolved with this HPLC system, but elute together in peak 6. Peak 5 is the major adduct formed in vivo by tamoxifen and was also formed by trans α-acetoxytamoxifen in vitro. Adducts in peak 5 probably contain tamoxifen linked to a base other than deoxyguanosine, via the α position, and are possibly adenine adducts. Nevertheless, there is still the possibility that tamoxifen adducts that arise from a different metabolic pathway in the rat (e.g. ring epoxidation) could co-elute with the major adducts formed by α-hydroxylation. Tamoxifen adduct standards, in the deoxyguanosine 3Ј monophosphate form, which can be 32 P-postlabelled, need to be synthesized for the accurate and absolute identification of adducts within each HPLC peak. Minor adduct peaks HPLC peaks 8-12 form a less polar group of adducts that elute close together near the end of the HPLC run in a region of increasing acetonitrile/methanol. Peaks 11 and 12 are only observed in chromatograms in which 5 and 6 are also present, and are present in similar proportions, which indicates a likely relationship between the two pairs, and it is possible that the products in peaks 11 and 12 are dimers of the major adducts, 5 and 6, respectively. Alternatively, peaks 8-12 could represent unique adducts. They elute by HPLC in a region where there is an increase in the background level of radioactivity in control samples and could be the region where endogenous adducts elute.
Conclusion
We have described a novel HPLC system that has the ability to separate tamoxifen DNA adducts formed in vivo and in vitro into at least 13 different peaks. By TLC, a number of adducts are resolved, but the separation is much poorer than that achieved by this HPLC system. The resolving power of this technique strongly suggests that the major route of activation of tamoxifen to DNA binding species in rat and mouse liver, is via α-hydroxylation. Further activation of 4-hydroxytamoxifen by the peroxidase/H 2 O 2 system in vitro gives a more polar DNA adduct seen only at trace levels in liver DNA in vivo. This indicates that adducts formed via the 4-hydroxytamoxifen pathway account for only minor DNA adducts formed in rat and mouse liver by tamoxifen.
